Company: Biohaven Pharmaceuticals
Drug Type: Protein Biologic
Conditions: Spinocerebellar Ataxia
Mechanism Type: Glutamate Excitotoxicity Blocker
Mechanism: BHV-4157 is a glutamate modulator that aims to protect neurons by reducing glutamate excitotoxicity.
U.S. Status for ALS: N/A
 Trial in Adult Subjects With Spinocerebellar Ataxia Clinical trials.gov, 15 June 2017.
 Biohaven Receives FDA IND Approval for BHV-4157. Biohaven Pharmaceuticals, 5 July 2016. Accessed 29 June 2017 from http://biohavenpharma.com/biohaven-receives-fda-investigational-new-drug-application-ind-approval-for-bhv-4157/
Last updated June 29th, 2017